Elizabeth G. Nabel's most recent trade in Lyell Immunopharma Inc was a trade of 130,000 Option (right to buy) done . Disclosure was reported to the exchange on May 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 130,000 | 130,000 | - | - | Option (right to buy) | |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 16,233 | 16,233 | - | - | Restricted Stock Units | |
| Moderna | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 979 | 0 | - | - | Restricted Stock Units | |
| Moderna | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 979 | 3,084 (0%) | 0% | - | Common Stock | |
| Medtronic | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 84.04 per share. | 28 Apr 2025 | 2,083 | 17,831 (0%) | 0% | 84.0 | 175,055 | Ordinary Shares |
| Medtronic | Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 84.60 per share. | 28 Apr 2025 | 216 | 17,615 (0%) | 0% | 84.6 | 18,274 | Ordinary Shares |
| Accolade Inc | Elizabeth G. Nabel | Director | Sale or transfer of securities back to the company at price $ 7.03 per share. | 08 Apr 2025 | 41,982 | 0 | - | 7.0 | 295,133 | Common Stock |
| Accolade Inc | Elizabeth G. Nabel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Apr 2025 | 35,021 | 0 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Apr 2025 | 12,489 | 0 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 12,489 | 12,489 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 2,178 | 41,982 | - | 0 | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 2,178 | 0 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 2,179 | 39,804 | - | 0 | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 2,179 | 2,178 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 2,179 | 37,625 | - | - | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 2,179 | 4,357 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 35,021 | 35,021 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2024 | 9,196 | 0 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2024 | 9,196 | 35,446 | - | - | Common Stock | |
| Lyell Immunopharma Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 130,000 | 130,000 | - | - | Option (right to buy) | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2024 | 2,179 | 6,536 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2024 | 2,179 | 26,250 | - | - | Common Stock | |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 5,668 | 5,668 | - | - | Stock Option (Right to Buy) | |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2024 | 979 | 979 | - | - | Restricted Stock Units | |
| Moderna | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 732 | 0 | - | - | Restricted Stock Units | |
| Moderna | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 732 | 2,105 (0%) | 0% | - | Common Stock | |
| Medtronic | Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.89 per share. | 01 May 2024 | 192 | 15,674 (0%) | 0% | 80.9 | 15,531 | Ordinary Shares |
| Medtronic | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 80.86 per share. | 29 Apr 2024 | 2,165 | 15,866 (0%) | 0% | 80.9 | 175,062 | Ordinary Shares |
| Accolade Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 8,715 | 8,715 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,751 | 0 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 1,751 | 24,071 | - | - | Common Stock | |
| Accolade Inc | Elizabeth Nabel G. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2023 | 1,751 | 1,751 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2023 | 1,751 | 22,320 | - | - | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2023 | 1,752 | 20,569 | - | - | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2023 | 1,752 | 3,502 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 9,196 | 9,196 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 14,060 | 0 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2023 | 14,060 | 18,817 | - | - | Common Stock | |
| Lyell Immunopharma Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2023 | 1,752 | 4,757 | - | - | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2023 | 1,752 | 5,254 | - | - | Restricted Stock Units | |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 4,601 | 4,601 | - | - | Stock Option (Right to Buy) | |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 732 | 732 | - | - | Restricted Stock Units | |
| Medtronic | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 90.68 per share. | 01 May 2023 | 1,930 | 13,804 (0%) | 0% | 90.7 | 175,012 | Ordinary Shares |
| Medtronic | Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 90.23 per share. | 01 May 2023 | 169 | 13,635 (0%) | 0% | 90.2 | 15,249 | Ordinary Shares |
| Moderna | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 670 | 0 | - | - | Restricted Stock Units | |
| Moderna | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 670 | 1,373 (0%) | 0% | - | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 7,006 | 7,006 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2022 | 14,060 | 14,060 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2022 | 2,659 | 3,005 | - | - | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jul 2022 | 2,659 | 0 | - | - | Restricted Stock Units | |
| Lyell Immunopharma Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| Medtronic | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 1,697 | 12,080 (0%) | 0% | 0 | Ordinary Shares | |
| Medtronic | Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.11 per share. | 02 May 2022 | 262 | 11,818 (0%) | 0% | 103.1 | 27,015 | Ordinary Shares |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 4,061 | 4,061 | - | - | Stock Option (Right to Buy) | |
| Moderna | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 703 | 0 | - | - | Restricted Stock Units | |
| Moderna | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 703 | 703 (0%) | 0% | 0 | Common Stock | |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 670 | 670 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2021 | 2,659 | 2,659 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2021 | 346 | 0 | - | - | Restricted Stock Units | |
| Accolade Inc | Elizabeth G. Nabel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2021 | 346 | 346 | - | - | Common Stock | |
| Accolade Inc | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 346 | 346 | - | - | Restricted Stock Units | |
| Medtronic | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 1,334 | 10,353 (0%) | 0% | 0 | Ordinary Shares | |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2021 | 4,081 | 4,081 | - | - | Stock Option (Right to Buy) | |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2021 | 703 | 703 | - | - | Restricted Stock Units | |
| Medtronic | Elizabeth G. Nabel | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 129.97 per share. | 27 Apr 2021 | 426 | 9,019 (0%) | 0% | 130.0 | 55,367 | Ordinary Shares |
| Moderna | Elizabeth G. Nabel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 1,139 | 1,139 | - | - | Stock Option (Right to Buy) |